PRKAA1 and early-onset autosomal dominant Alzheimer disease: These results indicate that Artemether could be a new AMPK/GSK3β(ser9)/Nrf2 activator for the treatment of inflammation and oxidative stress and a potential therapeutic agent for Alzheimer's disease.